Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD-CDR-S in Operable Adenocarcinomas of the Esophagus or Gastroesophageal Junction
NCT00216008Phase 2Terminated
- Sponsor
- Moffitt Cancer Center
- Start
- Jul 2005
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of docetaxel, cisplatin in esophageal adenocarcinoma (EAC), adenocarcinoma of the gastroesophageal junction, sponsored by Moffitt Cancer Center. Started Jul 2005; status: terminated.
02
Drugs
docetaxelcisplatin
03
Conditions
esophageal adenocarcinoma (EAC)adenocarcinoma of the gastroesophageal junction
Beyond the preview
Go deeper on NCT00216008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216008.